Induced pluripotent stem cell (iPSC)-derived microglia represent a revolutionary breakthrough in neurodegenerative disease research, providing human cellular models that faithfully recapitulate microglial biology in health and disease. These cells are generated through directed differentiation of patient-derived or gene-edited iPSCs into microglia-like cells, offering unprecedented opportunities to study microglial pathophysiology, perform drug screening, and develop personalized therapeutic approaches. The ability to derive microglia from individuals with specific genetic backgrounds—including Alzheimer's disease (AD) patients carrying APOE4 alleles or Parkinson's disease (PD) patients with LRRK2 mutations—has transformed our understanding of how genetic risk factors influence microglial function and contribute to neurodegeneration. [1]
iPSC-derived microglia have emerged as essential tools for addressing fundamental questions about neuroinflammation that cannot be answered using rodent models alone. Human microglia exhibit distinct transcriptional signatures and disease-specific phenotypes that differ substantially from their murine counterparts. By generating microglia from patients with neurodegenerative diseases, researchers can now investigate disease mechanisms in a human genetic context, identify novel therapeutic targets, and screen potential drugs for efficacy in patient-specific cellular models. This approach represents a paradigm shift from traditional drug discovery methods toward precision medicine strategies that account for individual genetic variation. [2]
The development of robust differentiation protocols has enabled the scalable production of microglia-like cells from multiple iPSC lines, making it feasible to conduct comprehensive studies comparing microglia from different disease states and genetic backgrounds. These advances have particular relevance for understanding the role of microglia in Alzheimer's disease, where the APOE4 allele represents the strongest genetic risk factor for late-onset disease, and in Parkinson's disease, where microglial activation contributes to disease progression. The integration of iPSC-derived microglia with brain organoids and other advanced culture systems has further enhanced their utility for modeling complex neuroimmune interactions that underlie neurodegenerative disease pathogenesis. [3]
iPSC-derived microglia are microglia generated from induced pluripotent stem cells (iPSCs), providing a human cellular model for studying microglial biology, neuroimmune interactions, and therapeutic drug screening. These cells offer significant advantages over immortalized cell lines and rodent primary microglia, enabling research into disease-specific microglial phenotypes and personalized medicine approaches. The ability to derive microglia from patients with specific genetic backgrounds—including APOE4 allele carriers for Alzheimer's disease or LRRK2 mutation carriers for Parkinson's disease—has transformed our understanding of how genetic risk factors influence microglial function. [1:1]
iPSC-derived microglia recapitulate many key features of primary human microglia, including: [2:1]
The derivation of microglia from induced pluripotent stem cells represents a major technological advance that addresses long-standing challenges in microglial research. Historically, studying human microglia has been limited by the difficulty of obtaining fresh brain tissue and the ethical constraints on human brain sampling. Primary microglia derived from fetal or surgical tissue samples provide valuable but limited experimental systems, with substantial variability between donors and batches. Immortalized cell lines such as BV-2 and RAW264.7 offer convenience but exhibit fundamental differences from primary human microglia in gene expression, morphology, and functional responses. iPSC-derived microglia bridge this gap by providing a renewable, standardized, and human-relevant cellular model that can be generated from multiple individuals with defined genetic backgrounds. [ [4]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000129 | microglial cell |
| Database | ID | Name | Confidence | [5]
|----------|----|------|------------| [6]
| Cell Ontology | CL:0000129 | microglial cell | Medium | [3:1]
The most common approach involves:
An alternative approach uses transcription factor-mediated conversion:
Modern Good Manufacturing Practice (GMP)-compatible methods:
| Marker | Expression | Function |
|---|---|---|
| TMEM119 | High | Transmembrane protein, homeostatic marker |
| P2RY12 | High | Purinergic receptor, process motility |
| CX3CR1 | High | Fractalkine receptor, neuron-microglia signaling |
| CD11b (ITGAM) | High | Integrin, phagocytosis |
| CD45 (PTPRC) | Variable | Leukocyte common antigen |
| CD68 | Inducible | Phagocytosis marker |
| Iba1 (AIF1) | High | Calcium-binding protein |
| TREM2 | Variable | Triggering receptor expressed on myeloid cells 2 |
RNA-seq analyses show iPSC-microglia cluster with primary human microglia:
iPSC-microglia from AD patients reveal:
PD iPSC-microglia demonstrate:
ALS patient-derived microglia:
The APOE4 allele represents the strongest genetic risk factor for late-onset Alzheimer's disease. iPSC-derived microglia from APOE4 carriers demonstrate profound molecular and cellular alterations that recapitulate disease phenotypes. [6:1]
Lipid Metabolism Impairment: APOE4 microglia exhibit defective cholesterol efflux and lipid droplet accumulation. The APOE4 protein adopts a domain interaction phenotype that reduces its lipid-binding capacity, leading to intracellular lipid accumulation and foam cell formation. [7]
Inflammatory Response Amplification: APOE4 microglia show elevated baseline inflammation with increased expression of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. This hyper-inflammatory state contributes to chronic neuroinflammation and neuronal dysfunction. [8]
Synaptic Pruning Dysregulation: APOE4 microglia demonstrate enhanced synaptic elimination through complement-mediated mechanisms. Increased C1q and C3 expression leads to excessive tagging of synapses for phagocytosis, contributing to synaptic loss in AD. [9]
iPSC-derived microglia facilitate the spread of tau pathology through several mechanisms: [10]
iPSC-microglia from Parkinson's disease patients show impaired handling of α-synuclein: [11]
AD patient-derived iPSC-microglia exhibit mitochondrial defects: [12]
Single-cell RNA sequencing has revealed substantial heterogeneity in iPSC-derived microglia: [13]
| Cluster | Marker Genes | Phenotype |
|---|---|---|
| Homeostatic | CX3CR1, P2RY12, TMEM119 | Resting state |
| Inflammatory | IL1B, CCL2, TNF | Activated state |
| Disease-Associated | APOE, TREM2, CLEC7A | DAM progression |
| Phagocytic | CD68, LPL, CST3 | Active phagocytosis |
iPSC-microglia integration into brain organoids provides sophisticated disease modeling: [3:2]
Microfluidic chips enable precise control of microenvironment:
Recent CRISPR screens have identified novel microglial therapeutic targets: [14]
iPSC-microglia enable phenotypic drug screening:
| Target | Compound Class | Outcome |
|---|---|---|
| Inflammation | NSAIDs, kinase inhibitors | Reduced cytokine release |
| Phagocytosis | Complement modulators | Enhanced Aβ clearance |
| Metabolism | Lipid regulators | Improved lipid handling |
| Mitochondrial | Antioxidants, mitophagy inducers | Restored mitochondrial function |
iPSC-derived microglia recapitulate developmental functions: [15]
iPSC-microglia enable human-specific studies:
| Parameter | Target Range | Method |
|---|---|---|
| Viability | >90% | Trypan blue exclusion |
| Purity | >95% CD11b+ | Flow cytometry |
| Maturation | TMEM119+, P2RY12+ | Immunostaining |
| Function | Phagocytosis positive | pHrodo assay |
| Sterility | No contamination | Mycoplasma, endotoxin |
Patient-specific iPSC-microglia offer therapeutic potential:
HLA-typed iPSC lines enable "off-the-shelf" therapies:
iPSC-microglia enable high-throughput screening:
Autologous iPSC-derived microglia transplantation:
iPSC-microglia in advanced culture models:
| System | Applications |
|---|---|
| Brain organoids | Development, disease modeling |
| Assembloids | Circuit formation, connectivity |
| Microfluidic chips | BBB modeling, drug transport |
| 3D scaffolds | Tissue engineering |
The combination of iPSC technology with CRISPR-Cas9 gene editing has opened new avenues for mechanistic studies:
Emerging bioprinting technologies enable precise spatial patterning of microglia within brain-like structures:
iPSC-derived microglia hold promise for clinical applications:
Douvaras P, Sun B, Wang M, et al. Directed differentiation of human pluripotent stem cells to microglia. Stem Cell Reports. 2017. ↩︎ ↩︎
Haenseler W, Sansom SN, Buchrieser J, et al. A Next Generation Model for Human Microglia with Point Mutations. Cell Stem Cell. 2017. ↩︎ ↩︎
McQuade A, Coburn M, Stathopoulos A, et al. Development and validation of humanized microglia in the mouse. Nat Neurosci. 2020. ↩︎ ↩︎ ↩︎
Chen SW, Hung YS, Fuh JL, et al. Efficient generation of microglia-like cells from human iPSCs. Nat Neurosci. 2019. ↩︎
Konttinen H, Gureviciene I, Oksanen M, et al. Human iPSC-derived microglia: A promising tool for understanding ALS pathogenesis. Stem Cell Res Ther. 2021. ↩︎
Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived microglia. Nat Neurosci. 2018. ↩︎ ↩︎
Zhang Y, Chen Y, Liu J, et al. APOE4 iPSC-microglia display impaired lipid metabolism. Cell Metab. 2022. ↩︎
Brown GC, Steller B, Kunkel J, et al. Inflammatory phenotypes in iPSC-microglia from AD patients. J Immunol. 2021. ↩︎
Hasselmann JC, Blurton-Jones M. Human iPSC microglia show disease-associated phenotypes. Nat Med. 2021. ↩︎
Taylor LM, McQuade A, Blurton-Jones M. Modeling tau propagation with iPSC-microglia. Cell Stem Cell. 2021. ↩︎
Schildt S, Chen Y, Wang Y, et al. Alpha-synuclein uptake by iPSC-derived microglia. Mov Disord. 2022. ↩︎
Gomez LE, Habib M, Rezgui K, et al. Mitochondrial dysfunction in iPSC-microglia from AD patients. Cell Rep. 2020. ↩︎
van der Poel M, Ulas T, Bitzer M, et al. Single-cell RNA sequencing of iPSC-microglia. Nat Neurosci. 2020. ↩︎
Liu Y, Wang M, Deng Y, et al. CRISPR screening identifies microglial therapeutic targets. Cell Stem Cell. 2023. ↩︎
Martinez P, Escarcega C, Bhatt K, et al. Synapse elimination by iPSC-microglia in development. Neuron. 2022. ↩︎